We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Boehringer Ingelheim Prolongates Drug Discovery Collaboration with Priaxon

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Boehringer Ingelheim Prolongates Drug Discovery Collaboration with Priaxon"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Priaxon, utilizing its proprietory PriaXplore® platform for small molecule drug discovery, and Boehringer Ingelheim will prolongate their research and development collaboration on mdm2/p53 inhibitors for the treatment of cancer.

The companies will continue working jointly to identify and advance drug candidates into pre-clinical development.

Thereafter, Boehringer Ingelheim will drive the development and commercialization of the potential cancer treatments arising from the collaboration.

"Priaxon has been able to develop promising mdm2/p53 inhibitors with its PriaXplore® technology", said Dr Juergen Kolb, CEO of Priaxon.

Dr Kolb continued, "We are proud that Boehringer Ingelheim appreciates Priaxon as a competent partner by prolongating the collaboration to advance the high potency lead compounds. We enjoy the fair and creative atmosphere of this cooperation very much."

Priaxon is entitled to up to EUR 86 million in milestone payments upon achievement of certain development, regulatory and commercial milestones as well as royalties on potential future net sales of products.